Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes

Abstract

Background In 2015, Zimbabwe introduced third-line antiretroviral therapy (ART) through four designated treatment centers; three government clinics in Harare and Bulawayo, and Newlands Clinic (NC), operated by a private voluntary organization in Harare. We describe characteristics of patients receiving third line ART and analyzed treatment outcomes in this national programme as of 31 December 2018. Methods We described the population using proportions for categorical variables, and medians and interquartile ranges for continuous variables. Patients from NC, where data were more complete, were followed from the date of starting third-line ART until death, transfer, loss to follow up or 31 December 2018. Results A total of 209 patients had ever received third-line ART: 124 at NC and 85 from the three government clinics. HIV genotype results were available for 89 (72%) patients at NC and fourteen (16.5%) patients in the government clinics. Median duration of third line ART (years) in the government clinics was 2.3 (IQR:0.6-3.4), 1.3 (IQR: 0.7-1.7) and 1 (0.6-1.9). Of the 67 patients who received third line ART in the government clinics for at least six months, 53 (79%) had most recent viral load (VL) < 1000 copies/ml. Data on other treatment outcomes from government clinics were incomplete. From NC: a total of 109 (88%) patients were still in care, 13 (10.5%) had died and 2 (1.5%) were transferred. Median duration of third-line ART was 1.4 years (IQR: 0.6-2.8). Among the 111 NC patients who had received third-line ART for at least 6 months, 83 (75%) had a VL <50 copies/ml and 106 (95.5%) had a VL <1000 copies/ml.

Treatment Modification after Second-Line Failure among People Living with HIV in Asia-Pacific

“…There was no association between treatment modification and subsequent survival. There is limited literature comparing survival outcomes after secondline treatment failure, however, studies have reported up to 26% mortality among those who have failed but remained on second-line [11] and 5-11% among those who have switched to third-line [3,15,24,25]. Our study observed a mortality rate of 3.9/100PYS for those who did not have a treatment modification, and 3.0/100PYS for those who did without ART interruption.…”

Risk factors for HIV virological non‐suppression among adolescents with common mental disorder symptoms in Zimbabwe: a cross‐sectional study

“…Out of 102 children and adolescents in Harare with virological failure in 2012, 67.6% had ≥1 clinically significant mutation [ 28 ]. There is increased emphasis on treatment switching in international guidelines [ 29 ], informed by a growing recognition of high resistance rates among ALWH [ 30 ]. In this study the highest prevalence of non‐suppression, by far, was in District 1, a border town with high HIV prevalence.…”

A feasibility study using time-driven activity-based costing as a management tool for provider cost estimation: lessons from the national TB control program in Zimbabwe in 2018

“…Lessons drawn from this study, therefore, can be applied to the rest of centres that provide TB services. The urban polyclinics had limited capacity in diagnosing, yet the volume of patients on treatment was similar to hospitals [ 10 ].…”